2 min read Business Ideas Destiny Pharma PLC unveils further positive results for c-difficile treatment as market research points to its commercial potential January 27, 2022 Marlon Hausner NTCD-M3, which researchers are readying to phase III clinical trials, was the subject to...
2 min read Business Inquiries Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment June 4, 2021 Marlon Hausner CEO Neil Clark claimed: “We have manufactured important progress due to the fact closing...